Table 2 Use of migraine preventive therapies (oral drugs and botulinum toxin) among triptan-treated migraineurs with unmet medical needs (UMN) (overall cohort and stratified for the average triptan dose units per month) in the first year of follow-up
|  | Overall UMN migraineurs | Average triptan dose units per month in 1 year | ||
|---|---|---|---|---|
4–9 | 10–14 | > 14 | ||
pLF-EM | pHF-EM | pCM | ||
| Â | 31,515 | 22,2796 | 5467 | 3252 |
Oral Preventive Therapies in the 1st year | ||||
 Treated with at least one drug (%) | 21.3 | 18.8 | 25.2 | 32.8 |
  1 drug (% of treated subjects) | 82.9 | 84.9 | 82.0 | 75.7 |
  2 drugs (% of treated subjects) | 15.1 | 13.8 | 15.4 | 20.2 |
  3 drugs (% of treated subjects) | 1.8 | 1.1 | 2.4 | 3.8 |
  4 drugs (% of treated subjects) | 0.2 | 0,2 | 0,2 | 0,3 |
 Active substance: | ||||
  Amitriptyline (%) | 9.4 | 8.5 | 11.1 | 13.0 |
  Topiramate (%) | 6.3 | 5.0 | 8.5 | 12.0 |
  Propranolol (%) | 3.3 | 2.8 | 4.1 | 5.3 |
  Atenolol (%) | 2.7 | 2.6 | 2.5 | 4.1 |
  Valproic acid (%) | 1.8 | 1.4 | 2.0 | 3.9 |
  Pizotifen (%) | 1.0 | 0.8 | 1.2 | 2.4 |
  Metoprolol (%) | 0.6 | 0.6 | 0.7 | 1.1 |
  Timolol (%) | 0.3 | 0.3 | 0.3 | 0.3 |
Botulinum Toxin in the 1st year | ||||
 Treated (%) | 0.3 | 0.2 | 0.5 | 1.0 |